ADC Therapeutics SA (NYSE:ADCT)
$ 3.261 0.051 (1.59%) Market Cap: 315.17 Mil Enterprise Value: 134.61 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 45/100
Back to the Transcripts List

Q2 2024 ADC Therapeutics SA Earnings Call Transcript

Aug 06, 2024 / 12:30PM GMT
Release Date Price: $2.92 (+1.74%)

Key Points

Positve
  • Achieved commercial profitability with ZYNLONTA in 2024, generating $34.9 million in revenue year-to-date.
  • Positive interim results from the LOTIS-5 Phase III study, with full enrollment expected by the end of 2024.
  • Strong progress in solid tumor programs, including ADCT-601 targeting AXL, with initial updates expected in the second half of 2024.
  • Disciplined capital allocation strategy, reducing operating expenses by 23% year-over-year on a non-GAAP basis.
  • Extended cash runway into mid-2026 due to recent financing of $105 million, providing a stronger balance sheet.
Negative
  • Quarter-over-quarter revenue decrease, with second quarter revenues of $17 million compared to $19.2 million in the same period in 2023.
  • Continued competition in the third-line plus DLBCL space, impacting market share.
  • Variability in ZYNLONTA sales due to ordering patterns and competition from bispecifics.
  • Net loss of $36.5 million for the quarter on a GAAP basis, indicating ongoing financial challenges.
  • Uncertainty around the timing and outcome of regulatory approvals and inclusion in treatment guidelines for new indications.
Operator

Welcome to the ADC Therapeutics second quarter 2024 financial results conference call. My name is Didi, and I will be your operator for today's call. (Operator Instructions)

I will now turn the call over to Marcy Graham, Investor Relations Officer for ADCT. Marcy, you may begin.

Mary Graham
ADC Therapeutics SA - IR

Thank you, operator. This morning, we issued a press release announcing our second quarter 2024 financial results and business update. This release and the slides we will use in today's presentation are available on the Investors section of the ADC Therapeutics website.

I'm joined on today's call by our Chief Executive Officer, Ameet Mallik; and our CFO, Pepe Carmona. We will discuss recent business highlights and review our second quarter 2024 financial results. We will then open the call for questions.

Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the US Private

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.